AWM
RCKT icon

Avior Wealth Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Avior Wealth Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,195
Closed -$101K – 761
2025
Q1 		$101K Hold
15,195
– – ﹤0.01% 697
2024
Q4 		$191K Sell
15,195
-1,304
-8% -$19.6K 0.01% 713
2024
Q3 		$305K Buy
16,499
+473
+3% +$9.69K 0.01% 584
2024
Q2 		$345K Buy
16,026
+1,259
+9% +$28.9K 0.01% 531
2024
Q1 		$398K Sell
14,767
-1,330
-8% -$37.8K 0.02% 512
2023
Q4 		$482K Sell
16,097
-1,670
-9% -$36.9K 0.03% 357
2023
Q3 		$364K Buy
17,767
+1,487
+9% +$27K 0.02% 404
2023
Q2 		$323K Sell
16,280
-894
-5% -$18.1K 0.02% 435
2023
Q1 		$294K Buy
17,174
+2,269
+15% +$44.4K 0.02% 455
2022
Q4 		$292K Buy
14,905
+1,114
+8% +$20.5K 0.02% 406
2022
Q3 		$220K Buy
13,791
+405
+3% +$6.32K 0.02% 438
2022
Q2 		$184K Buy
13,386
+5,328
+66% +$63.5K 0.02% 430
2022
Q1 		$127K Sell
8,058
-1,233
-13% -$21.3K 0.01% 480
2021
Q4 		$202K Buy
9,291
+714
+8% +$19.5K 0.02% 429
2021
Q3 		$256K Hold
8,577
– – 0.02% 397
2021
Q2 		$379K Buy
8,577
+49
+0.6% +$2.13K 0.04% 338
2021
Q1 		$378K Sell
8,528
-35
-0.4% -$1.92K 0.04% 330
2020
Q4 		$469K Sell
8,563
-1,767
-17% -$64.4K 0.06% 283
2020
Q3 		$236K Sell
10,330
-1,330
-11% -$32.8K 0.03% 359
2020
Q2 		$244K Buy
11,660
+1,450
+14% +$26.1K 0.04% 360
2020
Q1 		$142K Buy
10,210
+2,210
+28% +$43.8K 0.03% 388
2019
Q4 		$182K Sell
8,000
-150
-2% -$2.5K 0.03% 383
2019
Q3 		$94K Buy
8,150
+2,390
+41% +$29.7K 0.02% 414
2019
Q2 		$86K Buy
+5,760
New +$101K 0.02% 421

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Avior Wealth Management's RCKT Position: Q2 2025 in Review

Avior Wealth Management sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 15,195 shares — an estimated $101K sold.

Avior Wealth Management first reported a position in RCKT in Q2 2019 and held it in 24 quarters. The position peaked at $482K in Q4 2023. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Avior Wealth Management reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Avior Wealth Management sold 15,195 Rocket Pharmaceuticals shares in Q2 2025, an estimated $101K.
  • Avior Wealth Management first reported a position in Rocket Pharmaceuticals in Q2 2019 and held it in 24 quarters.
  • Avior Wealth Management's Rocket Pharmaceuticals position peaked at $482K in Q4 2023.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Avior Wealth Management's 13F filing for Q2 2025, filed 17 Jul 2025.